Jane Pollner, MD
Infectious Disease · Fairfax, VANPI 1265459812
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.8% of the total across 373 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Viiv Healthcare Company at 25.1% of the total. Among infectious disease clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 373 payments — averaging $22.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$2K
- Gilead$2K
- Merck$791
- Theratechnologies Inc.$510
- AbbVie$452
- Johnson & Johnson$414
- plus $2K from 19 others
What the payments were for
- Speaking & faculty fees$1322%
- Food & beverage$7,65193%
- Education$4646%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 96 | $2,072 |
| Gilead | 83 | $1,873 |
| Merck | 44 | $791 |
| Theratechnologies Inc. | 20 | $510 |
| AbbVie(2 entities) | 17 | $452 |
| Johnson & Johnson(2 entities) | 22 | $414 |
| Shionogi Inc | 16 | $303 |
| Napo Pharmaceuticals Inc | 16 | $300 |
| Melinta Therapeutics, LLC | 11 | $235 |
| Janssen Products, LP | 3 | $228 |
| Insmed, Inc. | 9 | $193 |
| Astellas Pharma US Inc | 4 | $170 |
| La Jolla Pharmaceutical Company | 6 | $142 |
| Paratek Pharmaceuticals, Inc. | 6 | $119 |
| Aimmune Therapeutics, Inc. | 4 | $101 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $90 |
| Pfizer | 4 | $90 |
| Ferring Pharmaceuticals Inc. | 2 | $43 |
| Mylan Institutional Inc. | 1 | $21 |
| Philips North America LLC | 1 | $19 |
| Vyera Pharmaceuticals, LLC | 1 | $19 |
| Dynavax Technologies Corporation | 1 | $17 |
| Janssen Scientific Affairs, LLC | 1 | $17 |
| Smith+Nephew | 1 | $13 |
| Tactile Systems Technology Inc | 1 | $12 |
How this compares
$8,247 in reported general payments places this provider in the 90th percentile of 194 infectious disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 93 | $402,633 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 37 | $157,248 |
| TivicayDolutegravir Sodium | 49 | $134,538 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 25 | $97,052 |
| DescovyEmtricitabine/Tenofov Alafenam | 36 | $88,524 |
| DovatoDolutegravir Sodium/Lamivudine | 30 | $87,841 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 13 | $60,213 |
| PrezcobixDarunavir/Cobicistat | 16 | $50,534 |
| JulucaDolutegravir/Rilpivirine | 12 | $41,469 |
| EdurantRilpivirine Hcl | 12 | $18,571 |
| Darunavir | 11 | $16,759 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 11 | $9,587 |
| Daptomycin | 18 | $6,484 |
| Rosuvastatin Calcium | 19 | $1,977 |
| CeftriaxoneCeftriaxone Sodium | 14 | $515 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $1,873 | $648,405166 claims |
| Viiv Healthcare CompanyTivicay, Triumeq, Dovato, Juluca | $2,072 | $360,900116 claims |
| Janssen Products, LPSymtuza | $228 | $60,21313 claims |
| Johnson & JohnsonPrezcobix | $414 | $50,53416 claims |
| Janssen Scientific Affairs, LLCEdurant | $17 | $18,57112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 194 infectious disease providers in Virginia.
Other infectious disease in Fairfax
- Stephen WeinrothFairfax$157K
- Marsha SoniFairfax$12K
- Trevor UyemuraFairfax$7K
- Alexander BagasraFairfax$5K
- Vijender BajwaFairfax$4K
- Gelareh AlaviFairfax$691
- Murliya GowdaFairfax$684
- Christopher BettacchiMarion$243K
- William PetriCharlottesville$92K
- Michael IsonFalls Church$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.